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1. Introduction 
In order to better understand the molecular and 
genetic mechanisms of cellular responses to bioactive 
poiypeptides, such as peptide hormones and growth 
factors, through interaction with specific receptors 
[l-3] we have been undertaking an approach using 
the strategy of mutagenesis [4,5]. We have devised a 
new selection procedure to isolate insulin receptor- 
deficient mutants by using a cytotoxic insulin cross- 
linked to diphtheria toxin A-fragment and proposed 
a possible mechanism of cell killing [6,7]. Recently, 
this technique has enabled us to isolate several vari- 
ants from mouse Swissl3T3 fibroblasts which have 
lost insulin binding ability and insulin responsiveness 
([8], submitted). 
Here, we have appfied the crosslinking method to 
a potent mitogen, epidermal growth factor (EGF, 
Mr 6045) [2]. Fragment A of diphtheria toxin (DTa; 
Mr 21 150) [9] was coupled via a disulfide bond to a 
cystamine~erivatized EGF. The crosslinked mole- 
cules were purified by Biogel P-10 column chroma- 
tography. The purified EGF-DTa conjugate was 
shown to inhibit the binding of ‘251-labeled EGF to 
cell surface receptors. It revealed strong cytotoxicity 
to human epidermoid carcinoma cells, A43 1, pos- 
sessing a high number of EGF receptors while it was 
ineffective to mouse NR-6 cells which are EGF recep- 
tor-deficient variants from Swiss/3T3 fibroblasts. 
These data strongly suggest hat the EGF-DTa con- 
jugate delivers catalytically active toxin A-fragment 
into A431 cells through EGF receptor-mediated 
endocytosis and inactives elongation factor 2 by 
ADP-ribosylation, 
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2. Mate&Is and methods 
Diphtheria toxin A-fragment was prepared as in 
[6]. Epidermal growth factor was purified from 
mouse submaxillary glands by the method in [IO]. 
EGF-DTa conjugation was done as in [6] with slight 
modification. Briefly, EGF (0.8 mg) was dissolved in 
1 ml 50 mM acetic acid and dialyzed against 2 changes 
of distilled water containing 1 pg phenylmethyl sul- 
fonyi fluoride (PMSF)~nll, 500 ml each. Cystamine 
dihydrochloride (225 mg) was added, dissolved and 
the pH was adjusted to 4.7 with 1 N HCl. 1-Ethyl-3- 
(3dimethyl aminopropyl) carbodiimide-HCI (EDAC, 
1.53 mg) was added and the pH maintained at 4.7 for 
10 min with gentle stirring. The reaction mixture was 
then dialyzed against 2 changes of 20 mM N-tris 
(hydroxymethy1~ methyl-2-aminoethane sulfonic acid 
(TES) (pH 6.5), 500 ml each, to remove unreacted 
cystamine dihydrochloride and EDAC. Diphtheria 
toxin A-fragment (1 mg) was reduced by incubating 
with 1 ml of 0.1 M dithiothreitol (DTT) at 4°C for 
4 h and then dialyzed against 1.5 1 20 mM TES 
(pH 6.5). About 0.6 ml reduced fragment A was 
added to 1 ml cystamine-EGF derivative and the pH 
was adjusted to 7.4. The mixture was dialyzed against 
1.5 1 of 20 mM TES (pH 7.4) containing I pg/ml 
PMSF for 18 h at 4°C to allow formation of spon- 
taneous disulfide bonds. 
2.1. Rmfication of EGF-DTa conjugate 
The conjugate (0.8 ml) was applied onto a column 
(1.4 X 28 cm) of Biogel P-IO pre-equilibrated with 
0.15 M NaCl in 50 mM HCl. The materials were eluted 
first with the same buffer, secondly with 20 mM TES 
(pH 7.4) and finally with 4 M urea in 20 mM TES 
(PI-I 7.4). Fractions of 1.4 ml were collected. 
ElsevierlNorth-Holland Biomedical Press 
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2.2. Inhibition of 12’I-EGF binding 
Cell cultures were maintained in Dulbecco‘s modi- 
fied Eagle (DME)-medium supplemented with 10% 
fetal calf serum, penicillin (100 U/ml) and strepto- 
mycin (100 &@/ml) under 5% C02-95% air and 
humidified atmosphere at 37’C. Confluent cell cul- 
tures in 60 mm diam. plastic petri dishes were placed 
on ice and washed twice with ice-cold EBSS buffer, 
2 ml each, as in [S]. The washed cells were then cov- 
ered with 1 ml EBSS buffer containing the desired 
amounts of EGF-DTa conjugate and incubated for 
10 mm at 23’C. Then, 10 ~1 ‘251-labeled EGF (150 
pCi/pg, 10 @i/ml, Collab. Res.) were added at 
1 .I X lo-” M final cont. After incubation for an 
additional 60 min at 23”C, the plates were washed 
3 times with ice-cold EBSS buffer, 3 ml each. The 
remaining radioactivity was counted as in [5]. Human 
epidermoid carcinoma cell line A43 1 [ 1 l] was 
obtained from Dr S. Cohen and mouse cell line NR-6 
[ 121 was kindly provided to us by Dr H. Herschman. 
2.3. Killing of cells 
This was done by adding EGF-DTa conjugate 
(0.002 Azsc units) into logarithmically growing cells 
in 35 mm diam. dishes. The change of morphology 
was monitored under a Nikon inverted phase-contrast 
microscope and photographed according to the 
manual. 
3. Results and discussion 
Highly pure DTa retains its ability to inactivate 
elongation factor 2 by ADP-ribosylation [9]. Each of 
such DTa fragments contains an SH-group which can 
be reacted with cystamine-derivatized EGF to form a 
disulfide bond at pH 7.4 (see section 2). When the 
reaction product was analyzed by polyacrylamide gel 
electrophoresis in the presence of sodium dodecyl- 
sulfate (SDS) (fig.lA) two major bands, I and II; 
appeared in addition to a strong band corresponding 
to unreacted DTa and a faint, broad band correspond- 
ing to EGF-cystamine derivatives. Incubation of the 
reaction mixture with 2-mercaptoethanol eliminated 
bands I and II, revealing only the two bands co-mi- 
grating with DTa and EGFcystamine derivatives 
(fig.lB). The broad appearance of the latter band is 
presumably due to heterogeneity of cystamine-treated 
EGF. This is expected since EGF contains several 
carboxyl groups [2] which could have reacted with 
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Fig.1. SDS-polyacrylamide (10%) gel electrophoresis of con- 
jugation products, showing two components of crosslinked 
molecules. Before (A) and after (B) treating with 2 mercapto- 
ethanol to cleave disulfide bonds. DTa and EGF indicate the 
migration positions of these markers in a separate channel. 
The electrophoresis conditions were 100 V, 18 mA/slab gel 
for 135 min by the method in [ 151. 
cystamine. These data clearly indicate the presence 
of disulfide linkage in the molecules of band I and 
band II. 
The reaction mixture was then loaded onto a col- 
umn of Biogel P-10 and the materials eluted succes- 
sively with 3 different elution buffers as is illustrated 
in fig.2. Each eluate was dialyzed to remove salts and 
analyzed by a SDS-polyacrylamide gel electropho- 
resis under the same conditions as fig.1. Peak 1 
appeared at the position of 1.8 column vol. at which 
EGF is supposed to be eluted as observed by others 
under identical conditions [lo]. Analysis of peak 1 
material on the polyacrylamide gel in fact revealed a 
broad band corresponding to EGF-cystamine deriva- 
tives. Peak 2 contained a single component with mobil- 
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Fig.2. Purification of conjugation products by Biogel P-10 
column chromatography. 
ity identical to that of band II. After reduction of this 
peak 2 material, two bands were detected which corre- 
spond to EGF-cystamine derivatives and DTa. Peak 3 
appeared to be a mixture of band I and band II mate- 
rials. From these data we conclude that peak 2 mate- 
rial is a conjugate of cystamine-derivatized EGF and 
DTa, linked via disulfide bond and free from EGF or 
its cystamine-derivatives. According to their migra- 
tion positions, it is probable that band I is either a 
DTa dimer or (DTa),-EGF and that band II is a 1: 1 
conjugate of DTa and EGF. 
The purified EGF-DTa conjugate, peak 2 mate- 
rial, was tested for its ability to compete with ‘*‘I- 
labeled intact EGF for binding to cell surface recep- 
tors. Inhibition of binding is clearly seen in fig.3, 
demonstrating that the EGF moiety of the conjugate 
recognizes specific EGF receptors expressed on the 
surface of human and mouse cells. About 0.0003 -42s~ 
units of conjugate was needed to obtain 50% inhibition 
on mouse 3T3 cells under the binding conditions used. 
About 7-times more conjugate was required to gain the 
same degree of inhibition on human A43 1 cells. This is 
consistent with the observations that A43 1 cells 
express an extraordinarily high number of EGF recep- 
tors [11,13]. 
Human cells are generally more susceptible to 
intact diphtheria toxin (DT) than are mouse cells and 
can be killed since DT or DTa, which has been uptaken 
into cells, shuts off protein synthesis in a highly spe- 
cific and efficient manner [9]. DTa fragments are not 
cytotoxic to cells because they are incapable of enter- 
ing cells due to a lack of cell surface binding sites [9]. 
Our preparation of pure DTa did not contain any 
trace of intact DT [6] and did not interfere with the 
growth of A43 1 cells. Human A43 1 cells, however, 
showed apparent morphology changes when they 
were cultivated in the presence of pure EGF-DTa 
conjugate (fig.4). Cell fragmentation occurred within 
24 h and the destruction continued with further 
incubation. Within 4-6 days all of the cells had died. 
We have tested another cell line, NR-6, which is of 
mouse origin and is deficient in EGF receptors [ 121. 
When NR-6 cells were treated in the same manner as 
A43 1 cells they grew normally to confluency. Thus, 
cell killing is related to the presence or absence of 
specific EGF receptors. 
We have described the synthesis of a cytotoxic 
EGF crosslinked to the catalytic fragment of diphthe- 
ria toxin and demonstrated that its cytotoxicity is 
dependent upon specific EGF receptors. These data 
A431 
Fig.3. Inhibition of 1251-EGF binding to human A431 and 
mouse 3T3 cells by the EGF-DTa conjugate. Confluent 
monolayer cultures were treated with the indicated volume 
of the conjugate solution (0.112 A 180 units/ml) for 10 min at 
23°C and then incubated with ‘*51-EGF for an additional 
60 min. The rells were extensively washed and the remaining 
radioactivity counted. 
Fig.4. Killing of human epidermoid carcinoma cells, A431 line, by the EGF-DTa conjugate. Subconfluent A431 cells were treated 
with 0.001 A,,, units/ml conjugate for 24 h (B) and for 48 h (D). Drastic cell destruction can be seen compared to the control 
cultures, (A) for 24 h and (C) for 48 h. 
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provide additional evidence to our proposal [6,8] 
that a bioactive polypeptide with a relatively small 
molecular weight can be crosslinked to DTa without 
loss of receptor recognizing activity and serve as a 
delivery vehicle of the toxic fragment A into viable 
cells. In this context, it should be noted that specifi- 
cally bound EGF is internalized by A43 1 cells and 
processed through the lysosomal pathway [ 13,141. 
The EGF-DTa conjugate is being used as a selection 
agent for mutants which are defective in EGF-recep- 
tor functions in order to provide them for further 
study of the genetic basis of EGF-receptor inter- 
actions [5]. 
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